ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ATRN-119’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ATRN-119 overview
ATRN-119 is under development for the treatment of advanced solid tumors including ovarian cancer, endometrial cancer, cervical cancer, colon cancer, breast cancer and prostate cancer. The drug candidate is administered through oral route. It acts by targeting ataxia telangiectasia and rad3-related (ATR). These are developed based on Atrize platform technology.
See Also:
Aprea Therapeutics overview
Aprea Therapeutics is a biopharmaceutical company that develops cancer therapeutics that reactivate mutant tumor suppressor protein, p53. Its DDR products pipeline includes ATRN-119 and ATRN-W1051. The company also offers products such as APR-246 drugs and therapeutics for myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and additional hematologic and solid tumor malignancies. It also has pre-clinical research and development to extend its product development. The company operates offices in Sweden and the US. Aprea Therapeutics is headquartered in Doylestown, Pennsylvania, the US.
For a complete picture of ATRN-119’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
